Clinical Trials Logo

Pseudomonas clinical trials

View clinical trials related to Pseudomonas.

Filter by:
  • None
  • Page 1

NCT ID: NCT06113107 Recruiting - Pseudomonas Clinical Trials

Impact of Modifications to the Rendering of the Antibiogram on the Prescriptions of Meropenem in Pseudomonas Bacteremia

Mero-Pyo
Start date: March 1, 2023
Phase:
Study type: Observational

Modification of the rendering of the antibiogram at the Strasbourg University Hospital in November 2019 with the appearance of the concept of "standard dose" or "high dose" sensitivity. This modification seems to have favored an inappropriate overprescription of Meropenem (the only antibiotic made "at standard dose") in Pseudomonas infections sensitive to other beta-lactams. In June 2021, it was therefore decided to mask sensitivity to carbapenems by default in the rendering of Pseudomonas antibiograms when the strain was sensitive to a narrower spectrum beta-lactam ("restricted" antibiogram). The aim of this study is to evaluate the impact of these changes in the antibiogram on antibiotic prescriptions.

NCT ID: NCT04596319 Completed - Cystic Fibrosis Clinical Trials

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

SWARM-Pa
Start date: December 22, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1b/2a, double-blind, randomized, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability and phage recovery profile of AP-PA02 multi-bacteriophage therapeutic candidate administered by inhalation in subjects with cystic fibrosis and chronic pulmonary Pseudomonas aeruginosa (PA) infection.

NCT ID: NCT02894684 Completed - Cystic Fibrosis Clinical Trials

Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis

AZTEC-CF
Start date: January 2017
Phase: Phase 4
Study type: Interventional

This study evaluates the role of AZLI in the treatment of acute pulmonary exacerbations of CF. For consecutive exacerbations patients will receive AZLI + IV Colistin, or two IV anti-pseudomonals.